Last reviewed · How we verify
nsclc neoadjuvant
Approved treatments
Clinical guidelines
- FDA label — neoadjuvant
For the treatment of adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. - FDA label — neoadjuvant|adjuvant
For the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-authorized test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- nsclc neoadjuvant patent landscape — cliff calendar, originator estates, attackable patents
- nsclc neoadjuvant treatment landscape brief
- nsclc neoadjuvant treatment updates RSS
Frequently asked questions about nsclc neoadjuvant
What are the treatment guidelines for nsclc neoadjuvant?
FDA label publishes guidelines for nsclc neoadjuvant. 2 guideline references tracked.
Related
- Treatment landscape: nsclc neoadjuvant patent cliff · nsclc neoadjuvant CI report
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing